---
document_datetime: 2025-12-29 07:24:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/glivec.html
document_name: glivec.html
version: success
processing_time: 0.1446189
conversion_datetime: 2025-12-31 02:48:23.035442
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Glivec

[RSS](/en/individual-human-medicine.xml/66979)

##### Authorised

This medicine is authorised for use in the European Union

imatinib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Glivec](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78606)
- [More information on Glivec](#more-information-on-glivec-843)
- [More information on Glivec](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Glivec. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Glivec.

Expand section

Collapse section

## What is Glivec?

Glivec is a medicine that contains the active substance imatinib. It is available as capsules (50 and 100 mg) and tablets (100 and 400 mg).

## What is Glivec used for?

Glivec is an anticancer medicine. It is used to treat the following diseases:

- chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control. Glivec is used when the patients are 'Philadelphia chromosome positive' (Ph+). This means that some of their genes have re-arranged themselves to form a special chromosome called the Philadelphia chromosome. Glivec is used in adults and children who have been newly diagnosed with Ph+ CML and who are not eligible for a bone marrow transplant. It is also used in adults and children in the 'chronic phase' of the disease if it is not responding to interferon alpha (another anticancer medicine), and in more advanced phases of the disease ('accelerated phase' and 'blast crisis');
- Ph+ acute lymphoblastic leukaemia (ALL), a type of cancer in which lymphocytes (another type of white blood cell) multiply too quickly. Glivec is used in combination with other anticancer medicines in adults and children who have been newly diagnosed with Ph+ ALL. It is also used alone to treat adults with Ph+ ALL that has returned following previous treatment, or is not responding to other medicines.
- myelodysplastic or myeloproliferative diseases (MD/MPD), a group of diseases in which the body produces large numbers of abnormal blood cells. Glivec is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR);
- advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control. Glivec is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFR?;
- gastrointestinal stromal tumours (GIST), a type of cancer (sarcoma) of the stomach and bowel, when there is uncontrolled growth of cells in the supporting tissues of these organs. Glivec is used to treat adults with GIST that cannot be removed with surgery or have spread to other parts of the body, and adults who are at risk of GIST coming back after surgical removal;
- dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably. Glivec is used to treat adults with DFSP that cannot be removed with surgery, and in adults who are not eligible for surgery when the cancer has returned after treatment or has spread to other parts of the body.

The medicine can only be obtained with a prescription.

## How is Glivec used?

Glivec treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood or solid tumours. Glivec is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut. The dose depends on the disease being treated, the age and condition of the patient, and the response to treatment, but it should not exceed 800 mg a day. For more information, see the package leaflet.

## How does Glivec work?

The active substance in Glivec, imatinib, is a protein-tyrosine kinase inhibitor. This means that it blocks some specific enzymes known as tyrosine kinases. These enzymes can be found in some receptors on the surface of cancer cells, including the receptors that are involved in stimulating the cells to divide uncontrollably. By blocking these receptors, Glivec helps to control cell division.

## How has Glivec been studied?

For CML, Glivec has been examined in four main studies involving 2,133 adults and one study of 54 children. These included a study involving 1,106 adults that compared Glivec with the combination of interferon alpha plus cytarabine (other anticancer medicines). This study measured how long the patients lived without their cancer getting worse.

For Ph+ ALL, Glivec has been examined in three studies involving 456 adults, including one study comparing Glivec with standard chemotherapy (medicines used to kill cancer cells) in 55 newly diagnosed patients. It has also been examined in a fourth main study involving 160 children and young people aged 1 to 22 years.

For GIST, Glivec has been examined in two main studies. One involved 147 patients whose GIST could not be surgically removed or had spread to other parts of the body, and looked at whether the tumours shrank in size. This study did not compare Glivec with any other medicines. The other study compared Glivec with placebo (a dummy treatment) in 713 patients whose cancer had been removed with surgery. This study measured how long the patients lived without their cancer coming back.

For MD/MPD (31 patients), HES and CEL (176 patients), and DFSP (18 patients), Glivec was not compared with any other medicines. These studies examined whether blood cell counts returned to normal levels, or whether the number of cancerous blood cells or the size of tumours fell.

## What benefit has Glivec shown during the studies?

Glivec was more effective than the comparator medicines. In patients with CML, the cancer had got worse in 16% of the patients taking Glivec after five years, compared with 28% of those taking interferon alpha plus cytarabine. Glivec was also better than standard chemotherapy in patients with Ph+ ALL. In patients with GIST that had been removed with surgery, patients taking Glivec lived for longer than those taking placebo without their cancer coming back. In the non-comparative studies of CML, Ph+ ALL and GIST, between 26 and 96% of patients showed a response to Glivec. In the study of patients aged 1 to 22 years who had Ph+ ALL, Glivec was shown to increase how long the patients lived without any major events (such as a relapse).

Due to their rarity, limited data were available for the other diseases, but around two thirds of the patients showed at least a partial response to Glivec.

## What is the risk associated with Glivec?

The most common side effects with Glivec (seen in more than 1 in 10 patients) are weight increase, neutropenia (low levels of the white blood cells that fight infection), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), headache, nausea (feeling sick), vomiting, diarrhoea, dyspepsia (indigestion), abdominal (tummy) pain, periorbital oedema (swelling around the eyes), rash, muscle spasm and cramps, muscle, bone and joint pain, fluid retention and fatigue (tiredness). For the full list of all side effects reported with Glivec, see the package leaflet.

Glivec must not be used in people who are hypersensitive (allergic) to imatinib or any of the other ingredients.

## Why has Glivec been approved?

The CHMP decided that Glivec's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Glivec

The European Commission granted a marketing authorisation valid throughout the European Union for Glivec on 7 November 2001.

Glivec : EPAR - Summary for the public

Reference Number: EMA/726040/2012

English (EN) (89.26 KB - PDF)

**First published:** 18/08/2009

**Last updated:** 24/07/2013

[View](/en/documents/overview/glivec-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-446)

български (BG) (116.84 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/bg/documents/overview/glivec-epar-summary-public_bg.pdf)

español (ES) (94.88 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/es/documents/overview/glivec-epar-summary-public_es.pdf)

čeština (CS) (113.61 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/cs/documents/overview/glivec-epar-summary-public_cs.pdf)

dansk (DA) (93.59 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/da/documents/overview/glivec-epar-summary-public_da.pdf)

Deutsch (DE) (91.7 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/de/documents/overview/glivec-epar-summary-public_de.pdf)

eesti keel (ET) (96.34 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/et/documents/overview/glivec-epar-summary-public_et.pdf)

ελληνικά (EL) (115.8 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/el/documents/overview/glivec-epar-summary-public_el.pdf)

français (FR) (96.17 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/fr/documents/overview/glivec-epar-summary-public_fr.pdf)

italiano (IT) (91.65 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/it/documents/overview/glivec-epar-summary-public_it.pdf)

latviešu valoda (LV) (111.7 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/lv/documents/overview/glivec-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (112.4 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/lt/documents/overview/glivec-epar-summary-public_lt.pdf)

magyar (HU) (111.41 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/hu/documents/overview/glivec-epar-summary-public_hu.pdf)

Malti (MT) (116.68 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/mt/documents/overview/glivec-epar-summary-public_mt.pdf)

Nederlands (NL) (92.23 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/nl/documents/overview/glivec-epar-summary-public_nl.pdf)

polski (PL) (113.74 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/pl/documents/overview/glivec-epar-summary-public_pl.pdf)

português (PT) (112.24 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/pt/documents/overview/glivec-epar-summary-public_pt.pdf)

română (RO) (110.49 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/ro/documents/overview/glivec-epar-summary-public_ro.pdf)

slovenčina (SK) (136.93 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/sk/documents/overview/glivec-epar-summary-public_sk.pdf)

slovenščina (SL) (125.34 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/sl/documents/overview/glivec-epar-summary-public_sl.pdf)

Suomi (FI) (92.11 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/fi/documents/overview/glivec-epar-summary-public_fi.pdf)

svenska (SV) (111.28 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

24/07/2013

[View](/sv/documents/overview/glivec-epar-summary-public_sv.pdf)

Glivec : EPAR - Risk-management-plan

English (EN) (38.81 MB - PDF)

**First published:** 12/02/2020

**Last updated:** 22/02/2024

[View](/en/documents/rmp/glivec-epar-risk-management-plan_en.pdf)

## Product information

Glivec : EPAR - Product Information

English (EN) (702.68 KB - PDF)

**First published:** 18/08/2009

**Last updated:** 12/11/2025

[View](/en/documents/product-information/glivec-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-1)

български (BG) (1.25 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/bg/documents/product-information/glivec-epar-product-information_bg.pdf)

español (ES) (556.92 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/es/documents/product-information/glivec-epar-product-information_es.pdf)

čeština (CS) (1.14 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/cs/documents/product-information/glivec-epar-product-information_cs.pdf)

dansk (DA) (1.02 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/da/documents/product-information/glivec-epar-product-information_da.pdf)

Deutsch (DE) (1.06 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/de/documents/product-information/glivec-epar-product-information_de.pdf)

eesti keel (ET) (1.02 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/et/documents/product-information/glivec-epar-product-information_et.pdf)

ελληνικά (EL) (657.14 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/el/documents/product-information/glivec-epar-product-information_el.pdf)

français (FR) (1.12 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/fr/documents/product-information/glivec-epar-product-information_fr.pdf)

hrvatski (HR) (1.08 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/hr/documents/product-information/glivec-epar-product-information_hr.pdf)

íslenska (IS) (1.04 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/is/documents/product-information/glivec-epar-product-information_is.pdf)

italiano (IT) (554.76 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/it/documents/product-information/glivec-epar-product-information_it.pdf)

latviešu valoda (LV) (1.12 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/lv/documents/product-information/glivec-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.17 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/lt/documents/product-information/glivec-epar-product-information_lt.pdf)

magyar (HU) (1.28 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/hu/documents/product-information/glivec-epar-product-information_hu.pdf)

Malti (MT) (1.4 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/mt/documents/product-information/glivec-epar-product-information_mt.pdf)

Nederlands (NL) (580.33 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/nl/documents/product-information/glivec-epar-product-information_nl.pdf)

norsk (NO) (577.08 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/no/documents/product-information/glivec-epar-product-information_no.pdf)

polski (PL) (1.09 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/pl/documents/product-information/glivec-epar-product-information_pl.pdf)

português (PT) (1.03 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/pt/documents/product-information/glivec-epar-product-information_pt.pdf)

română (RO) (1.09 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/ro/documents/product-information/glivec-epar-product-information_ro.pdf)

slovenčina (SK) (1.09 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/sk/documents/product-information/glivec-epar-product-information_sk.pdf)

slovenščina (SL) (1.03 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/sl/documents/product-information/glivec-epar-product-information_sl.pdf)

Suomi (FI) (1.07 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/fi/documents/product-information/glivec-epar-product-information_fi.pdf)

svenska (SV) (1.06 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

12/11/2025

[View](/sv/documents/product-information/glivec-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000290092 16/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Glivec : EPAR - All Authorised presentations

English (EN) (48.02 KB - PDF)

**First published:** 28/10/2005

**Last updated:** 04/08/2025

[View](/en/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-678)

български (BG) (56.27 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/bg/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.93 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/es/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.02 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/cs/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.24 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/da/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.29 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/de/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (48.28 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/et/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (55.03 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/el/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_el.pdf)

français (FR) (49.69 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/fr/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (51.12 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/hr/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (52.67 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/is/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.04 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/it/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (78.4 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/lv/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (53.22 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/lt/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (54.56 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/hu/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (72.72 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/mt/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (47.18 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/nl/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (51.51 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/no/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.22 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/pl/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.07 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/pt/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_pt.pdf)

română (RO) (51.69 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/ro/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (53.13 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/sk/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.1 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/sl/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (47.92 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/fi/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.91 KB - PDF)

**First published:**

28/10/2005

**Last updated:**

04/08/2025

[View](/sv/documents/all-authorised-presentations/glivec-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Glivec Active substance imatinib International non-proprietary name (INN) or common name imatinib Therapeutic area (MeSH)

- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Gastrointestinal Stromal Tumors
- Dermatofibrosarcoma
- Myelodysplastic-Myeloproliferative Diseases
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Hypereosinophilic Syndrome

Anatomical therapeutic chemical (ATC) code L01EA01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Glivec is indicated for the treatment of

- adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;
- adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;
- adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;
- adult patients with relapsed or refractory Ph+ ALL as monotherapy;
- adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;
- adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement.

The effect of Glivec on the outcome of bone-marrow transplantation has not been determined.

Glivec is indicated for:

- the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);
- the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;
- the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery.

In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

## Authorisation details

EMA product number EMEA/H/C/000406 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 26/07/2001 Marketing authorisation issued 07/11/2001 Revision 51

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Glivec : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (123.7 KB - PDF)

**First published:** 05/08/2025

**Last updated:** 12/11/2025

[View](/en/documents/procedural-steps-after/glivec-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Glivec : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (427.89 KB - PDF)

**First published:** 18/08/2009

**Last updated:** 12/11/2025

[View](/en/documents/procedural-steps-after/glivec-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Glivec-H-C-PSUSA-00001725-202105 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/176831/2022

English (EN) (127.53 KB - PDF)

**First published:** 05/04/2022

[View](/en/documents/scientific-conclusion/glivec-h-c-psusa-00001725-202105-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Glivec-PSUSA-00001725-201805 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Adopted

Reference Number: EMA/224414/2019

English (EN) (66.58 KB - PDF)

**First published:** 17/04/2019

[View](/en/documents/scientific-conclusion/glivec-psusa-00001725-201805-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Glivec-H-C-406-P46-0194 : EPAR - Assessment Report

Adopted

Reference Number: EMA/344123/2015

English (EN) (155.99 KB - PDF)

**First published:** 09/06/2015

**Last updated:** 09/06/2015

[View](/en/documents/variation-report/glivec-h-c-406-p46-0194-epar-assessment-report_en.pdf)

Glivec-H-C-406-II-0080 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/161314/2013

English (EN) (4.81 MB - PDF)

**First published:** 24/07/2013

**Last updated:** 24/07/2013

[View](/en/documents/variation-report/glivec-h-c-406-ii-0080-epar-assessment-report-variation_en.pdf)

Glivec : EPAR - Paediatric-investigation-plan compliance statement

Reference Number: EMA/161384/2013

English (EN) (70.47 KB - PDF)

**First published:** 24/07/2013

**Last updated:** 24/07/2013

[View](/en/documents/pip-compliance/glivec-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

CHMP post-authorisation summary of positive opinion for Glivec

Reference Number: EMA/CHMP/332285/2013

English (EN) (76.8 KB - PDF)

**First published:** 31/05/2013

**Last updated:** 31/05/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-glivec_en.pdf)

Glivec-H-C-406-II-0048 : EPAR - Assessment Report - Variation

English (EN) (223.25 KB - PDF)

**First published:** 17/08/2009

**Last updated:** 17/08/2009

[View](/en/documents/variation-report/glivec-h-c-406-ii-0048-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Glivec on 19 March 2009

Adopted

Reference Number: EMEA/CHMP/659495/2008

English (EN) (36.68 KB - PDF)

**First published:** 20/03/2009

**Last updated:** 20/03/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-glivec-19-march-2009_en.pdf)

Glivec-H-C-406-II-0035 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (301.12 KB - PDF)

**First published:** 08/05/2007

**Last updated:** 08/05/2007

[View](/en/documents/scientific-discussion-variation/glivec-h-c-406-ii-0035-epar-scientific-discussion-variation_en.pdf)

Glivec-H-C-406-II-0030 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (351.75 KB - PDF)

**First published:** 05/03/2007

**Last updated:** 05/03/2007

[View](/en/documents/scientific-discussion-variation/glivec-h-c-406-ii-0030-epar-scientific-discussion-variation_en.pdf)

Glivec-H-C-406-II-0031 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (271.09 KB - PDF)

**First published:** 05/03/2007

**Last updated:** 05/03/2007

[View](/en/documents/scientific-discussion-variation/glivec-h-c-406-ii-0031-epar-scientific-discussion-variation_en.pdf)

Glivec-H-C-406-II-0032 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (161.01 KB - PDF)

**First published:** 05/03/2007

**Last updated:** 05/03/2007

[View](/en/documents/scientific-discussion-variation/glivec-h-c-406-ii-0032-epar-scientific-discussion-variation_en.pdf)

Glivec : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (85.05 KB - PDF)

**First published:** 28/10/2005

**Last updated:** 28/10/2005

[View](/en/documents/steps-after-cutoff/glivec-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Glivec : EPAR - Procedural steps taken before authorisation

English (EN) (74.36 KB - PDF)

**First published:** 28/10/2005

**Last updated:** 28/10/2005

[View](/en/documents/procedural-steps/glivec-epar-procedural-steps-taken-authorisation_en.pdf)

Glivec : EPAR - Scientific Discussion

English (EN) (698.79 KB - PDF)

**First published:** 28/10/2005

**Last updated:** 28/10/2005

[View](/en/documents/scientific-discussion/glivec-epar-scientific-discussion_en.pdf)

#### News on Glivec

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2013) 31/05/2013

[Novartis withdraws its application to extend the marketing authorisation for Glivec](/en/news/novartis-withdraws-its-application-extend-marketing-authorisation-glivec) 23/10/2006

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Glivec : EPAR - Product information - tracked changes

English (EN) (247.58 KB - DOCX)

**First published:** 04/08/2025

**Last updated:** 12/11/2025

[View](/en/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-836)

български (BG) (296.12 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/bg/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_bg.docx)

español (ES) (275.1 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/es/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_es.docx)

čeština (CS) (264.96 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/cs/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (251.96 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/da/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (264.03 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/de/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (253.48 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/et/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (302.57 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/el/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_el.docx)

français (FR) (268.83 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/fr/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (273.08 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/hr/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (229.24 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/is/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_is.docx)

italiano (IT) (241.36 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/it/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (245.08 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/lv/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (247.31 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/lt/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (322.37 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/hu/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (274.67 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/mt/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (240.11 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/nl/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (253.53 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/no/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_no.docx)

polski (PL) (259.89 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/pl/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_pl.docx)

português (PT) (230.04 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/pt/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_pt.docx)

română (RO) (254.12 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/ro/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (247.01 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/sk/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (275.7 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/sl/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (241.65 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/fi/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (258.44 KB - DOCX)

**First published:**

04/08/2025

**Last updated:**

12/11/2025

[View](/sv/documents/product-information-tracked-changes/glivec-epar-product-information-tracked-changes_sv.docx)

#### More information on Glivec

Glivec was designated as an orphan medicine for the indications mentioned below. It is no longer an orphan medicine.

The orphan designation for [treatment of chronic myeloid leukaemia](/en/medicines/human/orphan-designations/eu301021) expired in November 2011 following a 10-year period of market exclusivity

The orphan designations for all other indications were withdrawn in April 2012 on the marketing authorisation holder's request.

- [Treatment of chronic myeloid leukaemia](/en/medicines/human/orphan-designations/eu301021) (14/02/2001).
- [Treatment of malignant gastrointestinal stromal tumours](/en/medicines/human/orphan-designations/eu301061) (20/11/2001).
- [Treatment of dermatofibrosarcoma protuberans](/en/medicines/human/orphan-designations/eu305305) (26/08/2005).
- [Treatment of acute lymphoblastic leukaemia](/en/medicines/human/orphan-designations/eu305304) (26/08/2005).
- [Treatment of chronic eosinophilic leukaemia and the hypereosinophilic syndrome](/en/medicines/human/orphan-designations/eu305320) (28/10/2005).
- [Treatment of myelodysplastic / myeloproliferative diseases](/en/medicines/human/orphan-designations/eu305340) (23/12/2005).

#### More information on Glivec

- [Glivec - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/glivec)
- [EMEA-000463-PIP02-10 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000463-pip02-10)
- [EMEA-000463-PIP01-08-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000463-pip01-08-m03)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 12/11/2025

## Share this page

[Back to top](#main-content)